Table 2

Patient demographics after match

Overall
N=11 022
Non-FCD
N=8253
(74.9%)
FCD
N=2769
(25.1%)
P value
Age, mean (SD)46.9 (16.4)46.9 (16.4)46.9 (16.6)0.876
Female sex5598 (50.8)4200 (50.9)1398 (50.5)0.714
Malnutrition502 (4.6)363 (4.4)139 (5.0)0.175
Payer type0.694
 Commercial9684 (87.9)7257 (87.9)2427 (87.7)
 Medicare1338 (12.1)996 (12.1)342 (12.3)
Anti-TNF therapy*4021 (36.5)3011 (36.5)1010 (36.5)0.993
CCI0.994
 05551 (50.4)4154 (50.3)1397 (50.5)
 12238 (20.3)1677 (20.3)561 (20.3)
 2+3233 (29.3)2422 (29.4)811 (29.3)
  • All data are n (%) unless otherwise stated.

  • *Anti-TNF therapy included adalimumab, certolizumab pegol, ustekinumab, vedolizumab, and infliximab.

  • CCI, Charlson Comorbidity Index; FCD, fibrostenotic Crohn’s disease; TNF, tumour necrosis factor.